Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
McKesson
QuintilesIMS
Novartis
Farmers Insurance
Healthtrust
US Department of Justice
Fish and Richardson
Merck
Boehringer Ingelheim

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,645,802

« Back to Dashboard

Which drugs does patent 7,645,802 protect, and when does it expire?

Patent 7,645,802 protects APLENZIN and is included in one NDA.

This patent has forty-nine patent family members in seventeen countries.
Summary for Patent: 7,645,802
Title:Bupropion hydrobromide and therapeutic applications
Abstract:Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
Inventor(s): Oberegger; Werner (Burlington, CA), Maes; Paul (Chatillon, FR), Saleh; Mohammad Ashty (Oakville, CA), Jackson; Graham (Co. Kildare, IE)
Assignee: Biovail Laboratories International SRL. (St. Michael, BB)
Application Number:11/930,644
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 7,645,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,645,802

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,569,611 Modified release formulations of a bupropion salt ➤ Subscribe
7,662,407 Modified release formulations of a bupropion salt ➤ Subscribe
7,241,805 Modified release formulations of a bupropion salt ➤ Subscribe
7,585,897 Modified release formulations of a bupropion salt ➤ Subscribe
8,932,628 Modified release formulations of a bupropion salt ➤ Subscribe
8,354,453 Bupropion hydrobromide and therapeutic applications ➤ Subscribe
7,671,094 Bupropion hydrobromide and therapeutic applications ➤ Subscribe
7,884,136 Modified-release formulations of a bupropion salt ➤ Subscribe
9,504,640 Modified release formulations of a bupropion salt ➤ Subscribe
7,553,992 Modified release formulations of a bupropion salt ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,645,802

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006261788 ➤ Subscribe
Australia 2008285660 ➤ Subscribe
Australia 2008320915 ➤ Subscribe
Canada 2578626 ➤ Subscribe
Canada 2655596 ➤ Subscribe
Canada 2699588 ➤ Subscribe
Canada 2700733 ➤ Subscribe
China 101534808 ➤ Subscribe
China 101784266 ➤ Subscribe
China 101903016 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Accenture
Citi
Fish and Richardson
Merck
Cipla
Dow
QuintilesIMS
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot